Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Padsevonil open-label extension in adults with drug-resistant focal-onset seizures
NL-OMON49972Phase 2Withdrawn
- Sponsor
- UCB
- Start
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of padsevonil in epilepsy and Focal Onset Epilepsy, sponsored by UCB. Primary endpoints: Change from baseline in observable focal-onset seizure frequency, Incidence of treatment-emergent adverse events and 1 more. Planned start May 2019; status: withdrawn.
02
Drugs
padsevonil
03
Conditions
epilepsyFocal Onset Epilepsy
Beyond the preview
Go deeper on NL-OMON49972.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49972.